Nanotechnology-based drug delivery systems for treatment of hyperproliferative skin diseases - a review

Current Nanoscience

Volumn 9, Issue 1, 2013, Pages 159-167

  dos Santos, Fernanda Kolenyak ^a   Oyafuso, Marcia Helena ^a   Kiill, Charlene Priscila ^a   Daflon Gremião, Maria Palmira ^a   Chorilli, Marlus ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Chronic hyperoproliferative diseases; Drug delivery systems; Nanotechnology; Psoriasis; Skin cancer; Skin diseases; Skin treatment

Indexed keywords

CONTROLLED DRUG DELIVERY; DERMATOLOGY; DISEASE CONTROL; DRUG INTERACTIONS; NANOTECHNOLOGY; TARGETED DRUG DELIVERY;

ANTI-PROLIFERATIVE; DRUG DELIVERY SYSTEM; DRUG RELEASE; PSORIASIS; SKIN CANCERS; SKIN DISEASE; SOLUBILITY IN WATERS; SYSTEMATIC REVIEW;

DISEASES;

AMINOLEVULINIC ACID; BENZOPSORALEN 3 ETHOXY CARBONYL 2H BENZOFURO[3,2 E] 1 BENZOPIRAN 2 ONE; CHITOSAN DERIVATIVE; CLOBETASOL PROPIONATE; CORTICOSTEROID; ETRETIN; FLUOROURACIL; GLYCEROL BEHENATE; KETOPROFEN; METHOTREXATE; METHOXSALEN; N SULFONATE N,O CARBOXYMETHYLCHITOSAN; NANOCAPSULE; NANOCOATING; PACLITAXEL; PHOSPHATIDYLCHOLINE; PODOPHYLLOTOXIN; POLOXAMER; POLYMER; POLYMERIC NANOPARTICLE; POLYMETHACRYLIC ACID; PSORALEN DERIVATIVE; RETINOIC ACID; SOLID LIPID NANOPARTICLE; SPANTIDE; TACROLIMUS; TEMOPORFIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ARTICLE; BIODEGRADABILITY; BURNING SENSATION; CELL DIFFERENTIATION; CELL VIABILITY; CHRONIC HYPERPROLIFERATIVE DISEASE; CONTACT DERMATITIS; CREAM; DERMATITIS; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG SAFETY; DRUG SOLUBILITY; ENCAPSULATION; ERYTHEMA; HUMAN; INJECTION SITE PRURITUS; IONTOPHORESIS; KERATINOCYTE; LIQUID CRYSTAL; MICROEMULSION; NANOMEDICINE; NANOTECHNOLOGY; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRECANCER; PRIORITY JOURNAL; PSORIASIS; PUVA; SKIN ALLERGY; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN PENETRATION; SKIN TUMOR; STRATUM CORNEUM; SYSTEMATIC REVIEW; T LYMPHOCYTE; TOPICAL TREATMENT; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 84875934477     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/1573413711309010027     Document Type: Article

References (135)

1. Prow, T.W.; Grice, J.E.; Lin, L.L.; Faye, R.; Butler, M.; Becker, W, Wurm, E.M.T.; Yoong, C.; Robertson, T.A.; Soyer, H.P.; Roberts, M.S. Nanoparti-cles and microparticles for skin drug delivery. Adv. Drug Deliv. Rev., 2011, 63, 470-491.
2. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Li, Y.; Wu, X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59, 491-504.
3. Goldman. Tratado de Medicina Interna. 21 ed. Rio de Janeiro 2001.
4. Griffiths, C.E.M.; Camp, R.D.R, Barker, J.N.W.N. Psoriasis. Rook's Text- book of Dermatology: Blackwell Publishing, Inc.; 2008, 1731-1800.
5. Griffiths, C.E. The immunological basis of psoriasis. J. Eur. Acad Dermatol. Venereol., 2003, 2,1-5.
6. Martins, G.A.; Arruda, L. Tratamento sistêmico da psoríase - Parte I: me-totrexato e acitretina. AnaisBrasileiros Dermatol., 2004,79, 263-278.
7. Thielen, A.M.; Laffitte, E. Topical treatments for psoriasis in 2009. Rev.Med. Suisse, 2009, 5, 878-881.
8. Nickoloff, B.J.; Schroder, J.M.; Driesch, P.; Raychaudhuri, S.P.; Farber, E.M.; Boehncke, W.H.; Morhenn, V.B.; Rosenberg, E.W.; Schön, M.P.; Hol-ick, M.F. Ispsoriasis a T-celldisease? Exp. Dermatol., 2000, 9, 359-375.
9. Raychaudhuri, S.elaP.; Farber, E.M. The prevalence of psoriasis in the world: J. Eur. Acad. Dermatol. Venereol., 2001, 15, 16-17.
10. Prinz JC. The role of T cells in psoriasis. J. Eur. Acad. Dermatol. Venereol., 2003, 17, 257-270.
11. Ortonne, N.; Ortonne, J.P. Psoriasis: pathogénie: Psoriasis. La Pressemédi-cale (1983) 1999, 28, 1259-1265.
12. Nickoloff, B. J. The search for pathogenic T cells and the genetic basis of psoriasis using a severe combined immunodeficient mouse model. Cutis (New York, NY), 2000, 65, 110-114.
13. Ortonne. Recent developments in the understanding of the pathogenesis of psoriasis. Br. J. Dermatol., 1999, 140, 1-7.
14. Friedrich, M.; Krammig, S.; Henze, M.; Döcke, W.D.; Sterry, W.; Asadullah, K. Flow cytometric characterization of lesional T cells in psoriasis: intracel-lular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch. Dermatol. Res., 2000, 292, 519-521.
15. Batchelor, J.M.; Ingram, J.R.; Williams, H. Adalimumabvs methotrexate for the treatment of chronic plaque psoriasis. Arch. Dermatol., 2009, 145,704-706.
16. Saurat J. Adalimumabvs methotrexate for the treatment of chronic plaque psoriasis-reply. Archives of Dermatology, 2009, 145, 704-706.
17. Carrascosa, J.M.; Vanaclocha, F.; Borrego, L.; Fernandez-Lopez, E.; Fuertes, A.; Rodriguez-Fernandez-Freire, L.; Zulaica, A.; Tuneu, A.; Caballé, G.; Co-lomé, E.; Bordas, X.; Hernanz, J.M.; Brufau, C.; Herrera, E. Update of the topical treatment of psoriasis. Actas Dermosifiliogr, 2009, 100, 190-200.
18. Naldi, L.; Raho, G. Emergingdrugs for psoriasis. Expert Opin. Emerg. Drugs, 2009, 14, 145-163.
19. Fang, S.; Fang, X.; Xiong, M. Psoriasis prediction from genome-wide SNP profiles. BMC Dermatol., 2011, 11,1.
20. Zhang, Y.; Li, J.; Lang, M.; Tang, X.; Li, L.; Shen, X. Folate-functionalized nanoparticles for controlled 5-Fluorouracil delivery. J. Colloid Interf. Sci., 2011, 354, 202-209.
21. Lindelöf, B.; Krynitz, B.; Ayoubi, S.; Martschin, C, Wiegleb-Edström, D.; Wiklund, K. Previous extensive sun exposure and subsequent vitamin D production in patients with basal cell carcinoma of the skin, has no protective effect on internal cancers. Eur. J. Cancer, 2012, 48, 1154-1158.
22. Tuohimaa, P.; Pukkala, E.; Scélo, G.; Olsen, J.H.; Brewster, D.H.; Hem-minki, K.; Tracey, E.; Weiderpass, E.; Kliewer E.V.; Pompe-Kirn, V.; McBride, M.l.; Martos, C.; Chia, K.S.; Tonita, J.M.; Jonasson, J.G.; Boffetta, P.; Brennan, P. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: Vitamin D as a possible explanation. Eur. J. Cancer, 2007, 43, 1701-1712.
23. Ministério da Saúde. Instituto Nacional de Câncer (INCA). Coordenação Nacional de Controle de Tabagismo - Contapp. Rio de Janeiro, Brasil 1996.
24. Fang, Y.P.; Tsai, Y.H.; Wu, P.C.; Huang, Y.B. Comparisonof 5-aminolevulinic acid-encapsulatedliposome versus ethosome for skindelivery for photodynamictherapy. Int. J. Pharm., 2008, 356, 144-152.
25. Lopez, R.F.V.; Lange, N.; Guy, R.; Bentley, M.V.L.B. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv. Drug Deliv. Rev., 2004, 56, 77-94.
26. Kim, S.C.; Yoon, H.J.; Lee, J.W.; Yu, J.; Park, E.S.; Chi, S.C. Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles. Int. J. Pharm., 2005, 293, 303-310.
27. Wu, J.Z.; Ho, P.C. Evaluation of the in vitro activity and in vivo bioavailabil-ity of realgar nanoparticles prepared by cryo-grinding. Eur. J. Pharm. Sci., 2006, 29, 35-44.
28. Lin, Y.K.; Huang, Z.R.; Zhuo, R.Z.; Fang, J.Y. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomedicine, 2010, 5, 117-128.
29. Katare, O.P.; Raza, K.; Singh, B.; Dogra, S. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian. J. Dermatol. Venereol. Leprol., 2010, 76, 612-621.
30. Shah, P.P.; Desai, P.R.; Patel, A.R.; Singh, M.S. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials, 2012, 33, 1607-1617.
31. Zhao, Y.; Moddaresi, M.; Jones, S.A, Brown, M.B. A dynamic topical hy-drofluoroalkane foam to induce nanoparticle modification and drug release in situ. Eur. J. Pharm. Biopharm., 2009, 72, 521-528.
32. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Bio-degradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 70, 1-20.
33. Uskokovic, D.; Stevanovic, M. Poly(lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins. Curr. Nano-science, 2009, 5, 1-14.
34. Patel N.R. Itraconazole loaded poly(lactic-co-glycolic) acid nanoparticles for improved antifungal activity. Thesis Master, 2007, 1-98.
35. Kim, D.H.; Martin, D.C. Sustained release of dexamethasone from hydro-philic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials, 2006, 27, 3031-3037.
36. Mundargi, R.C.; Babu, V.R; Rangaswamy, V.; Patel, P.; Aminabhavi, T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control. Release, 2008, 125, 193-209.
37. Agnihotri, S.A.; Mallikarjuna, N.N.; Aminabhavi, T.M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control. Release, 2004, 100, 5-28
38. Rudzinski, W.E.; Aminabhavi, T.M. Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm., 2010, 399, 1-11.
39. Jain, G.K.; Pathan, S.A.; Akhter, S.; Ahmad, N; Jain, N; Talegaonkar, S.; Khar, R.K.; Ahmad, F.J. Mechanistic study of hydrolytic erosion and drug release behaviour of PLGA nanoparticles: Influence of chitosan. Polym. De-grad. Stab., 2010, 95, 2360-2366.
40. Senyigit, T.; Sonvico, F.; Barbieri, S.; Özer, Ö.; Santi, P.; Colombo, P. Leci-thin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin. J. Control. Release, 2010, 142, 368-373.
41. Alvarez-Román, R.; Naik, A.; Kalia, Y.N.; Guy, RH.; Fessi, H. Enhancement of Topical Delivery from Biodegradable Nanoparticles. Pharm. Res., 2004, 21, 1818-1825.
42. Luengo, J.; Weiss, B.; Schneider, M.; Ehlers, A.; Stracke, F.; König, K.; Kostka, K.H.; Ler, CM.; Schaefer, U.F. Influence of Nanoencapsulation on Human Skin Transport of Flufenamic Acid. Skin Pharmacol. Physiol, 2006, 19, 190-197.
43. Desai, P.; Patlolla, R.R.; Singh, M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol. Membr. Biol, 2010, 27, 247-259.
44. Lademann, J.; Knorr, F.; Richter, H.; Blume-Peytavi, U.; Vogt, A.; Anto-niou, C; Sterry, W.; Patzelt, A. Hair Follicles - An Efficient Storage and Penetration Pathway for Topically Applied Substances. Skin Pharmacol. Physiol, 2008, 21,150-155.
45. Lademann, J.; Richter, H.; Teichmann, A.; Otberg, N; Blume-Peytavi, U.; Luengo, J.; Weiss, B.; Schaefer, U.F.; Lehr, CM.; Wepf, R.; Sterry, W. Nanoparticles - An efficient carrier for drug delivery into the hair follicles. Eur. J. Pharm. Biopharm., 2007, 66, 159-164.
46. Toll, R.; Jacobi, U.; Richter, H.; Lademann, J.; Schaefer, H.; Blume-Peytavi, U. Penetration Profile of Microspheres in Follicular Targeting of Terminal Hair Follicles. J. Investig. Dermatol, 2003, 123, 168-176.
47. Iscan, Y.; Hekimoglu, S.; Sargon, M.F.; Hincal, A.A. DEET-loaded solid lipid particles for skin delivery: In vitro release and skin permeation characteristics in different vehicles. J. Microencapsul, 2006, 23, 315-327.
48. Schäfer-Korting, M.; Mehnert, W.; Korting, H.C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev., 2007, 59, 427-443.
49. Attama, A.A, Reichl, S.; Müller-Goymann, C.C. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int. J. Pharm., 2008, 355, 307-313.
50. Babu, R.J.; Kikwai, L.; Jaiani, L.; Kanikkannan, N; Armstrong, C.A.; Ansel, J.C; Singh, M. Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist: Spantide II. Pharm. Res., 2004, 21, 108-113.
51. Kikwai, L.; Babu, R.J.; Kanikkannan, N; Singh, M. Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. J. Pharm. Pharmacol, 2004, 56, 19-25.
52. Shinkai, N; Korenaga, K.; Okumura, Y.; Mizu, H.; Yamauchi, H. Mi-crodialysis assessment of percutaneous penetration of ketoprofen after trans-dermal administration to hairless rats and domestic pigs. Eur. J. Pharm. Bio-pharm., 2011, 78, 415-421.
53. Stern, R.S. Psoralen and Ultraviolet A Light Therapy for Psoriasis. N. Engl. J. Med., 2007, 357,682-690.
54. Weber, F.; Schmuth, M.; Sepp, N.; Fritsch, P. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides. Acta Derm. Venereol., 2005, 85, 329-332.
55. Ito, T.; Aoshima, M.; Ito, N.; Uchiyama, I.; Sakamoto, K.; Kawamura, T.; et al. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Arch. Dermatol. Res., 2009, 301, 373-380.
56. Makki, S.; Muret, P.; Saïd, A.M.; Bassignot, P.; Humbert, P.; Agache, P.; Millet, J. Percutaneous absorption of three psoralens commonly used in therapy: Effect of skin occlusion (in vitro study). Int. J. Pharm., 1996, 133, 245-252.
57. Pires, A.E.; Honda, N.K.; Cardoso, C.A.L. A method for fast determination of psoralens in oral solutions of phytomedicines using liquid chromatography. J. Pharm. Biom. Analysis, 2004, 36, 415-420.
58. Canton, M.; Caffieri, S.; Dall'Acqua, F.; Di Lisa, F. PUVA-induced apoptosis involves mitochondrial dysfunction caused by the opening of the permeability transition pore. FEBS Lett., 2002, 522,168-172.
59. Gomes, A.J.; Faustino, A.S.; Lunardi, C.N.; Lunardi, L.O.; Machado, A.E. Evaluation of nanoparticles loaded with benzopsoralen in rat peritoneal exudate cells. Int. J. Pharm., 2007, 332, 153-160.
60. Lysenko, E.P.; Melnikova, V.O.; Andina, E.S.; Wunderlich, S.; Pliquett, F.; Potapenko, A.Y. Effects of glutathione peroxidase and catalase on hemolysis and methemoglobin modifications induced by photooxidizedpsoralen. J. Photochem. Photobiol. B, 2000, 56, 187-195.
61. da Hora, A.E.M.; de Miranda, J.A, de Oliveira-Campos, A.M.F.; Severino, D.; Ernest, N.D. Photophysical properties of two new psoralen analogs. J. Photochem. Photobiol. Chem., 2001, 146, 75-81.
62. Adisen, E.; Karaca, F.; Oztas, M.; Gurer, M.A. Efficacy of local psoralen ultraviolet A treatments inpsoriasis, vitiligo and eczema: Clin. Exp. Derma-tol., 2008, 33, 344-345.
63. Gambichler, T. Management of atopic dermatitis using photo(chemo) therapy. Arch. Dermatol. Res., 2009, 301, 197-203.
64. Mariano, T.M.; Vetrano, A.M.; Gentile, S.L.; Heck, D.E.; Whittemore, M.S.; Guillon, C.D.; et al. Cell-impermeantpyridinium derivatives of psoralens as inhibitors of keratinocyte growth. Biochem. Pharm., 2002, 63,31-39.
65. Said, A.; Makki, S.; Muret, P.; Humbert, P.; Millet, J. Psoralens percutaneous permeation across the human whole skin and the epidermis in respect to their polarity (in vitro study). J. Dermatol. Sci., 1997, 14, 136-144.
66. Serrano-Pérez, J.J.; González-Luque, R.; Merchán, M.; Serrano-Andrés, L. The family offurocoumarins: Looking for the best photosensitizer for phototherapy. J. Photochem. Photobiol. A Chem., 2008, 199, 34-41.
67. Tatchen, J.; Kleinschmidt, M.; Marian, C.M. Electronic excitation spectra and singlet-triplet coupling in psoralen and its sulfur and selenium analogs. J. Photochem. Photobiol. A Chem., 2004, 167, 201-212.
68. Tokura, Y. Modulation of cytokine production by 8-methoxypsoralen and UVA. J. Derm. Sci., 1999, 19, 114-122.
69. Wackernagel, A.; Hofer, A.; Legat, F.; Kerl, H.; Wolf, P. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. Br. J. Dermatol., 2006, 154, 519-523.
70. Creamer, D.; Martyn-Simmons, C.L.; Osborne, G.; Kenyon M.; Salisbury, J.R.; Devereux, S.; Paqliuca, A.; Ho, A.Y, Mufti, G.J. du Vivier, A.W. Ec-zematoid graft-vs-host disease: A novel form of chronic cutaneous graft-vs-host disease and its response to psoralen-uv-a therapy. Arch. Dermatol., 2007, 143, 1157-1162.
71. Middelkamp-Hup, M.A.; Pathak, M.A.; Parrado, C.; Garcia-Caballero, T.; Rius-Diaz, F.; Fitzpatrick, T.B.; González, S. Orally administered Polypodi-umleucotomos extract decreases psoralen-UVA-nducedphototoxicity, pigmentation, and damage of human skin. J. Am. Acad. Dermatol., 2004, 50, 41-49.
72. Lindelöf, B.; Krynitz, B.; Ayoubi, S.; Martschin, C.; Wiegleb-Edström, D.; Wiklund,K. Previous extensive sun exposure and subsequent vitamin D production in patients with basal cell carcinoma of theskin, has no protective effect on internal cancers. Eur. J. Cancer, 2012, 48, 1154-1158.
73. Lindelöf, B.; Sigurgeirsson, B.; Tegner, E.; Larkö, O.; Johannesson, A.; Berne, B.; Ljunggren, B.; Andersson, T.; Molin, L.; Nylander-Lundqvist, E.; Emtestam, L. PUVA and cancer risk: the Swedish follow-up study. Br. J. Dermatol., 1999, 141,108-112.
74. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 2004, 56, 1649-1659.
75. Kim, S.H.; Jeong, J.H.; Chun, K.W.; Park, T.G. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene gly-col)-folate conjugate. Langmuir, 2005, 21, 8852-8857.
76. Thanou, M.; Duncan, R. Polymer-protein and polymer-drug conjugates in cancer therapy. Curr. Opin. Investig. Drugs, 2003, 4, 701-709.
77. Yoo, H.S.; Park, T.G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release, 2004, 96, 273-283. 16
78. Reza, S.M.; Tabatabaie, R.M.; Maharramov, A.; Ali, R.M. Synthesis and in vitro studies of biodegradable modified chitosan nanoparticles for photody-namic treatment of cancer. Int.J.Biol. Macromol., 2011, 49, 1059-1065.
79. Ourique, A.F.; Melero, A.; Silva, C.B.; Schaefer, U.F.; Pohlmann, A.R.; Guterres, S.S.; Lehr, C.M.; Kostka, K.H.; Beck, R.C. Improved photo stability and reduced skin permeation of tretinoin: Development of a semisolid nanomedicine. Eur. J. Pharm. Biopharm., 2011, 79, 95-101.
80. Pardeike, J.; Hommoss, A.; Müller, R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm., 2009, 366, 170-184.
81. Müller, R.H.R.; Wissing, S.A. Solid Lipid Nanoparticles and Nanostruc-tured Lipid Carriers. Encyclopedia Nanosci. Nanotechnol., 2004, 10, 43-56.
82. Silva, A.C.; Santos, D.; Ferreira, D.C.; Souto, E.B. Minoxidil-loaded nanos-tructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. Die Pharmazie - An Int. J. Pharm. Sci., 2009, 64, 177-182.
83. Souza, A.L.R.; Kiill, C.P.; Santos, F.K.; Luz, G.M.; Silva, H.R.; Chorilli, M.; Gremião, M.P.D. Nanotechnology-based Drug Delivery Systems for Der-matomycosis Treatment. Curr. Nanosci, 2012, 8, 512-519.
84. Hu, F.Q.; Zhang, Y.; Du, Y.Z.; Yuan, H. Nimodipine loaded lipid nano-spheres prepared by solvent diffusion method in a drug saturated aqueous system. Int. J. Pharm., 2008, 348, 146-152.
85. Kumar, V.V.; Chandrasekar, D.; Ramakrishna, S.; Kishan, V.; Rao, Y.M.; Diwan, P.V. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceri de lipids on plasma pharmacoki-netics. Int. J. Pharm., 2007, 335, 167-175.
86. Radomska-Soukharev, A. Stability of lipid excipients in solid lipid nanopar-ticles. Adv. Drug Del. Rev., 2007, 59,411-418.
87. Saupe, A.; Gordon, K.C.; Rades, T. Structural investigations on nanoemul-sions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int. J. Pharm., 2006, 314, 56-62.
88. Souto, E.B.; Anselmi, C.; Centini, M.; Müller, R.H. Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles (SLN®) Int. J. Pharm., 2005, 295, 261-268.
89. Bondi, M.L.; Azzolina, A.; Craparo, E.F.; Capuano, G.; Lampiasi, N.; Giammona, G.; Cervello, M. Solid lipid nanoparticles containing nimesulide: preparation, characterization and cytotoxicity studies. Curr. Nanosci., 2009, 5, 39-44.
90. Müller, R.H.; Runge, S.A.; Ravelli, V.; Thünemann, A.F.; Mehnert, W.; Souto, E.B. Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug- lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm., 2008, 68, 535-544.
91. Tan, S.W.; Billa, N.; Roberts, C.R.; Burley, J.C. Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. Colloids Surf. A Physicochem. Eng. Asp., 2010, 372, 73-79.
92. Kovacevic, A.; Savic, S.; Vuleta, G.; Müller, R.H.; Keck, C.M. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and N LC): Effects on size, physical stability and particle matrix structure. Int. J. Pharm., 2011, 406, 163-172.
93. Agrawal, Y.; Petkar, K.C.; Sawant, K.K. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int. J. Pharm., 2010, 401, 93-102.
94. Joshi, M.; Patravale, V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int. J. Pharm., 2008, 346, 124-132.
95. Obeidat, W.M.; Schwabe, K.; Müller, R.H.; Keck, C.M. Preservation of nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm., 2010, 76, 56-67.
96. Wiedersberg, S.; Leopold, C.S.; Guy, R.H. Bioavailability and bioequivalence of topical glucocorticoids. Eur. J. Pharm. Biopharm., 2008, 68, 453-466.
97. Sivaramakrishnan, R.; Nakamura, C.; Mehnert, W.; Korting, H.C.; Kramer, K.D.; Schäfer-Korting, M. Glucocorticoid entrapment into lipid carriers - characterisation by parelectric spectroscopy and influence on dermal uptake. J. Control. Release, 2004, 97, 493-502.
98. Zhang, J.; Smith, E. Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles. J. Pharm. Sci., 2011, 100, 896-903.
99. Jensen, L.B.; Petersson, K.; Nielsen, H.M. In vitro penetration properties of solid lipid nanoparticles in intact and barrier-impaired skin. Eur. J. Pharm. Biopharm., 2011, 79, 68-75.
100. Liu, W.; Hu, M.; Liu, W.; Xue, C; Xu, H.; Yang, X. Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int. J. Pharm., 2008, 364, 135-141.
101. Maia, C.S.; Mehnert, W.; Schäfer-Korting, M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int. J. Pharm., 2000, 196, 165-167.
102. Shah, K.A.; Date, A.A.; Joshi, M.D.; Patravale, V.B. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int. J. Pharm., 2007, 345, 163-171. 17
103. Mandawgade, S.D.; Patravale, V.B. Development of SLNs from natural lipids: Application to topical delivery of tretinoin. Int. J. Pharm. 2008, 363, 132-138.
104. Knights, K.M.; Gasser, R.; Klemisch, W. In vitro metabolism of acitretin by human liver microsomes: evidence of an acitretinoyl-coenzyme Athioester conjugate in the transesterification to etretinate. Biochem. Pharmacol, 2000, 60, 507-516.
105. Stephanou, G.; Andrianopoulos, C; Tyrakis, M.; Konti, M.; Demopoulos, N.A.; Tsambaos, D. In vitro antigenotoxic potential of acitretin in human lymphocytes treated with the antineoplastic alkylating agent ASE (NSC-71964). Toxicol. inVitro, 2004, 18, 609-616.
106. Hadjipavlou-Litina, D.; Magoulas, G.E.; Krokidis, M.; Papaioannou, D. Syntheses and evaluation of the antioxidant activity of acitretin analogs with amide bond(s) in the polyene spacer. Eur. J. Med. Chem., 2010, 45, 298-310.
107. Loftsson, T.; Sigurdardóttir, A.M.; Ólafsson J.H. Improved acitretin delivery through hairless mouse skin by cyclodextrincomplexation. Int. J. Pharm., 1995, 115, 255-258.
108. Zahir, H.; Nand, R.A.; Brown, K.F.; Tattam, B.N.; McLachlan, A.J. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J. Pharm. Toxicol. Methods, 2001, 46, 27-35.
109. Spergel, J.M.; Leung, D.Y. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr. Allergy Asthma Rep., 2006, 6,270-274.
110. Pople, P.V.; Singh, K.K. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis Int. J. Pharm., 2010, 398, 165-178.
111. Fang, J.Y.; Fang, C.L.; Liu, C.H.; Su, Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanos-tructured lipid carriers (NLC). Eur. J. Pharm. Biopharm., 2008, 70, 633-640.
112. Palombo, P.; Fabrizi, G.; Ruocco, V.; Ruocco, E.; Fluhr, J.; Roberts, R. Morganti, P. Beneficial long-term effects of combined oral/topical antioxidant treatment with the carotenoids lutein and zeaxanthin on human skin: a double-blind, placebo-controlled study. Skin Pharmacol Physiol, 2007, 20, 199-210.
113. Mitri, K.; Shegokar, R.; Gohla, S.; Anselmi, C.; Müller, R.H. Lipid nanocar-riers for dermal delivery of lutein: Preparation, characterization, stability and performance. Int. J. Pharm., 2011, 414, 267-275.
114. Nikolic, S.; Keck, CM.; Anselmi, C.; Müller, R.H. Skin photoprotection improvement: Synergistic interaction between lipid nanoparticles and organic UV filters. Int. J. Pharm., 2011, 414, 276-284.
115. Piacentini, R.D.; Luccini, E.; Micheletti, M.I.; Quel, E.; Wolfram, E.A.; Pazmiño, A.F, et al Satellite and ground measurements of solar erythemal UV radiation and ozone in Argentina. Adv. Space Res., 2004, 34, 2221-2226.
116. Escobedo, J.F.; Gomes, E.N.; Oliveira, A.P.; Soares, J. Modeling hourly and daily fractions of UV, PAR and NIR to global solar radiation under various sky conditions at Botucatu, Brazil. Appl Energy, 2009, 86, 299-309.
117. Sanad, R.; AbdelMalak, N.; Bayoomy, T.; Badawi, A. Formulation of a Novel Oxybenzone-Loaded Nanostructured Lipid Carriers (NLCs). AAPS Pharm. Sci. Tech., 2010, 11, 1684-1694.
118. Formariz, T.P.; Urban, M.C.C.; Júnior, A.A.S.; Gremião, M.P.D.; Oliveira, A.G. Microemulsões e fases líquidas cristalinas como sistemas de liberação de fármacos. Rev. Bras. Cie. Farm., 2005, 41, 301-313.
119. Praça, F.S.G.; Medina, W.S.G.; Petrilli, R.; Bentley, M.V.L.B. Liquid crystal nanodispersions enable the cutaneous delivery of photosensitizer for topical PDT: fluorescence microscopy study of skin penetration. Curr. Nanosci, 2012, 5, 535-540.
120. Guterres, S.S.; Alves, M.P.; Pohlmann, A.R. Polymeric nanoparticles, nano-spheres and nanocapsules, for cutaneous applications. Drug Target Insights, 2007, 2, 147-157.
121. Resende, K.X.; Corrêa, M.A.; Oliveira, A.G.; Scarpa, M.V. Effect of cosur-factant on the supramolecular structure and physicochemical properties of non-ionic biocompatible microemulsions. Rev. Bras. Ciências Farm., 2008, 44, 35-42.
122. El Maghraby, G.M. Microemulsions as transdermaldrugdelivery systems. Curr. Nanosci., 2012, 8, 504-511.
123. D'Cruz, O.J.; Uckun, F.M. Gel-microemulsions as vaginal spermicidesandin-travaginaldrug delivery vehicles. Contraception, 2001, 64, 113-123.
124. Aboofazeli R, Barlow D, Lawrence MJ. Particle size analysis of concentrated phospholipid microemulsions II.Photon correlation spectroscopy. AAPS Pharm. Sci., 2000, 2, 19.
125. Kogan, A.; Garti, N. Microemulsions as transdermal drug delivery vehicles. Adv. Colloid Interface Sci., 2006, 126, 369-385.
126. Chorilli, M.; Prestes, P.S.; Rigon, R.B.; Leonardi, G.R.; Chiavacci, L.A.; Scarpa, M.V. Desenvolvimento de sistemas líquido-cristalinos empregando silicone fluido de co-polímero glicol e poliéter funcional siloxano. Química Nova, 2009, 32, 1036-1040.
127. Palma, S.; Manzo, R.; LoNostro, P.; Fratoni, L.; Allemandi, D.Vehiculización de AntralinaenCoageles de n-alquil derivados del Ácido Ascórbico. Lat. Am. J. Pharm., 2003, 22, 305-312.
128. Behera, J.; Keservani, R.K.; Yadav, A.; Tripathi, M.; Chadoker, A. Methox-salen loaded chitosan coated microemulsion for effective treatment of psoriasis, 2011.
129. Djordjevic, L.; Primorac, M.; Stupar, M.; Krajisnik, D. Characterization of caprylocaproylmacrogolglycerides based microemulsion drug delivery vehicles for an amphiphilic drug. Int. J. Pharm., 2004, 271, 11-19.
130. Delgado-Charro, M.B.; Iglesias-Vilas, G.; Blanco-Méndez, J.; López-Quintela, M.A.; Marty, J.P.; Guy, R.H. Delivery of a hydrophilic solute through the skin from novel microemulsion systems. Eur. J. Pharm. Bio-pharm., 1997, 43, 37-42.
131. Kreilgaard, M. Influence of microemulsions on cutaneous drug delivery. Adv. Drug Deliv. Rev., 2002, 54, Supplement: S77-S98.
132. Araújo, L.M.P.C.; Thomazine, J.A.; Lopez, R.F.V.Development of microe-mulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy. Eur. J. Pharm. Biopharm., 2010, 75, 48-55.
133. Bronaugh, R.L.; Maibach, H.I. Percutaneous absorption drugs, cosmetics, mechanisms, methodology. third ed. Boca Raton: Taylor & Francis; 2005.
134. Oyafuso, M.H. Desenvolvimento e caracterização de sistemas micro e nano-estruturados para a administração cutânea de acetato de dexametasona. Thesis Master, 2012, 1-87.
135. Gong, X.; Moghaddam, M.J.; Sagnella, S.M.; Conn, C.E.; Danon, S.J.; Wad-dington, L.J.; Drummond, C. J. Lyotropic liquid crystalline self-assembly material behavior and nanoparticulate dispersions of a phytanyl pro-drug analogue of capecitabine-a chemotherapy agent. ACS Appl. Mater. Interfaces, 2011, 3, 1552-1561.